HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SR-0379

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Pore Forming Cytotoxic Proteins
      - Antimicrobial Cationic Peptides: 414
        SR-0379: 4
- Peptides: 82426
  - Antimicrobial Peptides: 3727
    - Antimicrobial Cationic Peptides: 414
      - SR-0379: 4
  - Antimicrobial Cationic Peptides: 414
    - SR-0379: 4

Experts

1.	Nakagami, Hironori: 3 articles (11/2019 - 01/2014)
2.	Ando, Hiroshi: 2 articles (11/2019 - 01/2018)
3.	Ebihara, Tamotsu: 2 articles (11/2019 - 01/2018)
4.	Fujimoto, Taku: 2 articles (11/2019 - 01/2018)
5.	Hanaoka, Hideki: 2 articles (11/2019 - 01/2018)
6.	Hayashi, Misa: 2 articles (11/2019 - 01/2018)
7.	Ishikawa, Takahiro: 2 articles (11/2019 - 01/2018)
8.	Kiyohara, Eiji: 2 articles (11/2019 - 01/2018)
9.	Koshizaka, Masaya: 2 articles (11/2019 - 01/2018)
10.	Nakamura, Ayumi: 2 articles (11/2019 - 01/2018)

Related Diseases

1.	Leg Ulcer 01/01/2018 - "Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective." 01/01/2018 - "To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. " 11/01/2019 - "Treatment with SR-0379 was safe, well-tolerated, and effective for leg ulcers of both Werner syndrome and diabetes patients. " 11/01/2019 - "An investigator-initiated clinical study was carried out to evaluate the therapeutic potency of SR-0379 for the treatment of leg ulcers in patients with Werner syndrome. "
2.	Werner Syndrome (Werner's Syndrome) 11/01/2019 - "Treatment with SR-0379 was safe, well-tolerated, and effective for leg ulcers of both Werner syndrome and diabetes patients. " 11/01/2019 - "The reduction rate of ulcer size treated with 0.1% SR-0379 was 22.90% (mean) in the Werner syndrome ulcers group (n = 4) and 35.70% (mean) in the diabetic ulcers group (n = 4), respectively. " 11/01/2019 - "An investigator-initiated clinical study was carried out to evaluate the therapeutic potency of SR-0379 for the treatment of leg ulcers in patients with Werner syndrome. " 11/01/2019 - "Investigator-initiated clinical study of a functional peptide, SR-0379, for limb ulcers of patients with Werner syndrome as a pilot study."
3.	Skin Ulcer 11/01/2019 - "SR-0379 (0.1%) was sprayed on skin ulcers once per day for 4 weeks. " 01/01/2018 - "In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73% for the 0.02% SR-0379 group, 68.25% for the 0.1% group, and 71.61% for the 0.5% group, compared with 9.95% for the placebo group. " 01/01/2018 - "Twelve patients were randomized into four groups and administered 0.02%, 0.1%, or 0.5% SR-0379 or placebo treatment on skin ulcers once per day for 28 days. "
4.	Peripheral Arterial Disease 10/01/2017 - "The anti-microbial peptide SR-0379 stimulates human endothelial progenitor cell-mediated repair of peripheral artery diseases."
5.	Wounds and Injuries (Trauma) 01/01/2014 - "These results indicate that SR-0379 may have the potential for drug development in wound repair, even under especially critical colonization conditions. " 01/01/2014 - "We evaluated the effect of SR-0379 in two different would-healing models in rats, the full-thickness defects under a diabetic condition and an acutely infected wound with full-thickness defects and inoculation with Staphylococcus aureus. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)